MedTrace Logo

Joint Health Study

NCT03358836 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2022-06-22

No results posted yet for this study

Summary

This is a prospective, non-randomized, controlled study to examine whether or not having a higher trough during prophylactic treatment with clotting factor offers better joint protection than the standard trough of 1% Factor IX (FIX or Factor 9). This study will test the hypothesis that an extended half-life (EHL) FIX product with an intended trough of \>10% could offer better protection than previous treatment concentrates. This study also examines whether or not joint damage could be diagnosed earlier using ultrasound images.

Conditions

  • Hemophilia B

Sponsors & Collaborators

  • CSL Behring

    collaborator INDUSTRY

  • Bloodworks

    lead OTHER

Principal Investigators

  • Rebecca Kruse-Jarres, MD, MPH · Washington Center for Bleeding Disorders at Bloodworks Northwest

Eligibility

Min Age
16 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-15
Primary Completion
2020-08-17
Completion
2020-08-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03358836 on ClinicalTrials.gov